Literature DB >> 3718029

Malignant ascites. Clinical and experimental observations.

R N Garrison, L D Kaelin, R H Galloway, L S Heuser.   

Abstract

Malignant ascites formation is a grave prognostic sign, but palliative efforts seem justified in some patients. Lack of knowledge concerning the natural history of this process hinders the choice of therapeutic options. Over 5 years, 107 patients with untreated malignant ascites were reviewed to define their survival. Pancreas (20), ovary (18), and colon (18) were the most frequent tumors, with 52% of patients presenting with ascites at the time of the initial cancer diagnosis. Cytology evaluation of the ascitic fluid was positive for tumor cells in 57% of cases and a high protein content was noted in 65%. Mean survival of the entire series was only 20 weeks from the time of diagnosis of ascites, with tumors of ovarian and lymphatic origin having better mean survivals of 32 and 58 weeks, respectively. Patients with high ascitic protein levels fared better than those with low levels. In an effort to explain this correlation of elevated protein levels and a favorable survival rate, a hypothesis was proposed that certain tumors secrete a factor, which alters vascular permeability and causes fluid accumulation in the absence of lymphatic obstruction. In an experimental rat model of malignant ascites, the intraperitoneal infusion of cell-free malignant ascitic fluid caused an increase in edema formation and a significant increase in capillary permeability to protein in the omentum. This demonstrated change in the leak of protein explains the formation of ascites by some tumors in the absence of tumor obstruction of the draining lymphatics of the peritoneal cavity and suggests another important mechanism in the genesis of malignant ascites.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3718029      PMCID: PMC1251196          DOI: 10.1097/00000658-198606000-00009

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  14 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  Differences in vascular permeability between normal and tumor vessels produced by vasoactive agents.

Authors:  N B Ackerman
Journal:  Surg Forum       Date:  1973

3.  A study of ascites using lymphoscintigraphy with 99m Tc-sulfur colloid.

Authors:  G Coates; R S Bush; N Aspin
Journal:  Radiology       Date:  1973-06       Impact factor: 11.105

4.  New approach to management of malignant ascites with a streptococcal preparation, OK-432. I. Improvement of host immunity and prolongation of survival.

Authors:  M Torisu; M Katano; Y Kimura; H Itoh; M Takesue
Journal:  Surgery       Date:  1983-03       Impact factor: 3.982

5.  The accuracy of the physical examination in the diagnosis of suspected ascites.

Authors:  E L Cattau; S B Benjamin; T E Knuff; D O Castell
Journal:  JAMA       Date:  1982-02-26       Impact factor: 56.272

6.  Intracavitary chromic phosphate (32P) colloidal suspension therapy.

Authors:  G L Jackson; N M Blosser
Journal:  Cancer       Date:  1981-12-15       Impact factor: 6.860

7.  Pathogenesis of ascites in mice with peritoneal carcinomatosis.

Authors:  J Fastaia; A E Dumont
Journal:  J Natl Cancer Inst       Date:  1976-03       Impact factor: 13.506

8.  A quantitative measurement of peritoneal drainage in malignant ascites.

Authors:  M J Bronskill; R S Bush; G N Ege
Journal:  Cancer       Date:  1977-11       Impact factor: 6.860

9.  Prognostic analysis of malignant pleural and peritoneal effusions.

Authors:  S Yamada; T Takeda; K Matsumoto
Journal:  Cancer       Date:  1983-01-01       Impact factor: 6.860

10.  On the treatment and prognosis of malignant ascites: is the survival time determined when the abdominal paracentesis is needed?

Authors:  P Appelqvist; J Silvo; L Salmela; S Kostiainen
Journal:  J Surg Oncol       Date:  1982-08       Impact factor: 3.454

View more
  44 in total

1.  Malignant ascites: A review of prognostic factors, pathophysiology and therapeutic measures.

Authors:  Suma L Sangisetty; Thomas J Miner
Journal:  World J Gastrointest Surg       Date:  2012-04-27

2.  Rad51 promoter-targeted gene therapy is effective for in vivo visualization and treatment of cancer.

Authors:  Christopher M Hine; Andrei Seluanov; Vera Gorbunova
Journal:  Mol Ther       Date:  2011-10-18       Impact factor: 11.454

3.  The clinical significance of vascular endothelial growth factor in malignant ascites.

Authors:  Na Zhan; Wei-Guo Dong; Jing Wang
Journal:  Tumour Biol       Date:  2015-10-13

Review 4.  Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research.

Authors:  Emma Kipps; David S P Tan; Stan B Kaye
Journal:  Nat Rev Cancer       Date:  2013-02-21       Impact factor: 60.716

5.  Palliative treatment of malignant ascites: profile of catumaxomab.

Authors:  Lila Ammouri; Eric E Prommer
Journal:  Biologics       Date:  2010-05-25

6.  The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial.

Authors:  Markus M Heiss; Pawel Murawa; Piotr Koralewski; Elzbieta Kutarska; Olena O Kolesnik; Vladimir V Ivanchenko; Alexander S Dudnichenko; Birute Aleknaviciene; Arturas Razbadauskas; Martin Gore; Elena Ganea-Motan; Tudor Ciuleanu; Pauline Wimberger; Alexander Schmittel; Barbara Schmalfeldt; Alexander Burges; Carsten Bokemeyer; Horst Lindhofer; Angelika Lahr; Simon L Parsons
Journal:  Int J Cancer       Date:  2010-11-01       Impact factor: 7.396

7.  Palliative venting gastrostomy in patients with malignant bowel obstruction and ascites.

Authors:  Colette Shaw; Roland L Bassett; Patricia S Fox; Kathleen M Schmeler; Michael J Overman; Michael J Wallace; Sanjay Gupta; Alda Tam
Journal:  Ann Surg Oncol       Date:  2012-09-11       Impact factor: 5.344

8.  How valuable is ascitic cytology in the detection and management of malignancy?

Authors:  R O S Karoo; T D R Lloyd; G Garcea; H D Redway; G S R Robertson
Journal:  Postgrad Med J       Date:  2003-05       Impact factor: 2.401

9.  Biomarkers of malignant ascites-a myth or reality.

Authors:  Mithu Banerjee; Rajeshwar Singh; M M Arora; V Srinivas; D Basannar; Seema Patrikar
Journal:  Med J Armed Forces India       Date:  2011-07-21

Review 10.  Management of drainage for malignant ascites in gynaecological cancer.

Authors:  Alison Keen; Debbie Fitzgerald; Andrew Bryant; Heather O Dickinson
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.